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2020 has been the year of coronavirus disease 2019 (COVID-19), and all of us have been
affected. The impact on Neurology® Neuroimmunology, Neuroinflammation (N2) is reflected by
themany articles on a variety of COVID-19–related topics such as whether patients withMS and
other neuroimmunologic diseases are more vulnerable to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection1–7; how extending treatment dosing intervals (to reduce
the risk of viral infections) affects the course of MS8,9; and the possible effects of the virus on the
peripheral and CNS. An early review by Dr. Dalakas10 covered many of the potential compli-
cations of COVID-19 on the peripheral nervous system. In addition, multiple clinical case reports
described other infrequent COVID-19–related complications in the peripheral nervous system
and CNS including Guillain-Barré syndrome (GBS),11,12 acute encephalopathy attributed to
cytokines,13 acute necrotizing encephalitis and myelitis,14,15 complications suspected to be CNS
vasculitis (or vasculopathy),16,17 ophthalmoparesis and hypothalamic deficits caused by unclear
mechanisms,18 and studies on SARS-CoV-2 antibodies in CSF and blood-brain-barrier (BBB)
dysfunction potentially affecting neurologic outcome.19 Despite the lockdowns and confine-
ments (or perhaps because of them), the number of articles received in 2020 compared with the
same period in 2019 has increased in 95.8%. In 2020, the impact factor of the journal increased to
a competitive 7.724, which may have attracted some of these articles. Here, we review some
studies published this year in N2.
In many patients, the clinical significance of glutamic acid decarboxylase 65 (GAD65) antibodies
can be difficult to establish. These antibodies can be identified in many clinical scenarios in-
cluding type I diabetes mellitus, several neurologic syndromes such as cerebellar degeneration,
stiff-person syndrome, limbic encephalitis, seizures, and in up to 8% of healthy people.20 The
ability to detect the antibodies depends on the technique used, which from high to low sensitivity
include ELISA, radioimmunoassay, brain tissue immunohistochemistry (IHC), and cell-based
assays (CBAs), the latter 2 with a similar low sensitivity. However, for GAD65 antibody–
associated neurologic syndromes, the lower sensitivity assays (IHC andCBA) are not necessarily
the less useful, rather the opposite. The reason for this is that no cutoff values have been defined
for the high sensitive assays (ELISA or radioimmunoassay) to establish that neurologic symp-
toms are in fact linked to GAD65 autoimmunity. In contrast, clinical experience and expert
opinions have suggested that when antibodies are detected with low sensitive assays, particularly
in CSF, the associated neurologic symptoms are most likely related to GAD65 autoimmunity. In
line with this concept, some investigators indicate that a definite relationship can only be
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established if there is specific synthesis of intrathecal GAD65
antibodies.20 To determine the cutoff values of the tests in-
dicated above for the diagnosis of GAD65 antibody–associated
neurologic syndromes, Muñoz-Lopetegi and colleagues21 ex-
amined the serum and CSF (when available) of 56 patients
with several types of neurologic symptoms using ELISA, IHC,
and CBA.When the ELISA cutoffwas ≥100 IU/mL, all tests in
CSF showed 100% concordance. As far as serum was con-
cerned, when the ELISA cutoff was 10,000 IU/mL, all samples
with lower concentration of antibodies were negative by IHC,
whereas 97% of those with higher (>10,000 IU/mL) antibody
concentration were positive by IHC. Most IHC results cor-
responded well with CBA findings. Importantly, 34 (94%) of
36 patients with high-concentration (>10,000 IU/mL) anti-
bodies had typical GAD65 antibody-associated neurologic
syndromes (cerebellar ataxia, stiff-person syndrome, limbic
encephalitis, epilepsy, or overlapping syndromes). In contrast,
12 (60%) of the 20 patients with low-concentration (<10,000
IU/mL) antibodies had alternative diagnoses, and the other 8
patients had chronic epilepsy, otherwise seronegative limbic
encephalitis, or nonspecific ataxia and gait disorder. Immu-
notherapy was associated with a decrease in antibody con-
centration that frequently associated with partial clinical
improvement. The study confirmed that in patients with low
anti-GAD65 concentrations, particularly those without typical
GAD65-associated phenotypes, alternative diagnostic etiolo-
gies should be considered.
In 2016, Graus and colleagues22 reported an algorithmic
diagnostic approach to autoimmune encephalitis including
diagnostic criteria for some specific syndromes. The approach
was mainly based on experience with adult patients, although
data from children were also taken in consideration for some
diseases (e.g., anti-NMDAR encephalitis). To validate these
algorithmic diagnostic guidelines in children, de Bruijn and
colleagues23 investigated 113 children that were initially in-
cluded in 3 categories: (1) children with antibody-mediated
encephalitis (n = 21), (2) children with acute disseminated
encephalomyelitis (ADEM, n = 34), and (3) children with
neurologic symptoms suspected to be autoimmune (n = 60).
Overall, 103 children fulfilled the criteria of possible autoim-
mune encephalitis. Among the 21 cases with antibody-
mediated encephalitis, 19 had anti-NMDAR, 1 anti-AMPAR,
and 1 anti-LGI1 encephalitis. Among the rest of the patients,
34 eventually had ADEM, 2 Hashimoto encephalopathy, and
46 other diagnoses that included possible autoimmune/
inflammatory encephalitis (21), no evidence of autoimmune
encephalitis and other etiology identified (10), and no evi-
dence of autoimmune encephalitis and etiology unknown
(15). The mean incidence rates were 1.54 children/million for
antibody-mediated encephalitis and 2.49 children/million for
ADEM. Thus, except for anti-NMDAR encephalitis and
ADEM, other autoimmune encephalitis were uncommon in
children. The authors concluded that current diagnostic
guidelines for autoimmune encephalitis are also useful in
children. Yet, in children with nonspecific symptoms (n = 46,
45%), it was important to review the data critically, perform
comprehensive workup for alternative diseases, and consult
specialized neuroinflammatory centers. Almost in parallel with
this study, Celluci and colleagues24 as part of a subcommittee
of the Autoimmune Encephalitis InternationalWorkingGroup
specifically adapted the guidelines to children. The sub-
committee highlighted themain clinical features distinguishing
adults and children with autoimmune encephalitis and pro-
vided 3 diagnostic categories (possible, probable, and definite)
and a diagnostic algorithm. The task for the future is to validate
this pediatric algorithm with a large cohort of children sus-
pected to have autoimmune encephalitis.
One important challenge in the field of autoimmune and
paraneoplastic encephalitis is the sensitivity and specificity
of the clinical assays. To determine the accuracy of com-
mercial tests for antibodies against onconeuronal (in-
tracellular) paraneoplastic antigens, Déchelotte and
colleagues25 examined sera of 5,300 patients with suspected
paraneoplastic neurologic syndromes (PNSs) with 2 different
commercial immunoblot tests. The samples that were found
positive were additionally examined with confirmatory tests
that included rat brain IHC and a recombinant protein-based
assay, either CBA or in-house immunoblot. Using one of the
commercial tests, 128 (8%) of 1,658 sera were found positive,
and of these, only 47 (37%) were established as truly positive
for paraneoplastic antibodies. Using the other commercial test,
186 (5%) of 3,626 sera were positive, and of these, only 56
(30%) were identified as positive. The degree of correspon-
dence between the commercial assays and the confirmatory
tests varied broadly according to the antigens; for anti-Yo
(PCA1), only 7% and 6% of the samples found positive by the
commercial assays were eventually established as positive. In
contrast, for anti-Hu (ANNA1), 88% and 65% of samples
positive by commercial tests were confirmed with validation
assays. Most of the false-positive cases by commercial tests
were eventually diagnosed with nonparaneoplastic or auto-
immune diseases, and most did not even have cancer. There-
fore, although immunoblots may be useful for general
screening of paraneoplastic antibodies, a threshold should be
established for each antibody, and clinical information and
confirmation of results with other techniques are essential.
Another study from Xu and colleagues26 described 220 patients
with anti-NMDAR encephalitis. Overall, the clinical findings
and frequent improvement were similar to those reported in
other series from Europe or the United States. However, 17%
of the patients had relapses during the first 12months, which is
higher than previous studies (e.g., 12% over the first 2 years),
and the frequency of tumors was lower (19.5%) than that
previously reported (38%). In a separate study fromChina, Dr.
Peng and colleagues27 studied 111 patients with anti-NMDAR
encephalitis and validated the anti-NMDAR encephalitis 1-
year functional status (NEOS) score as a reliable predictor of
poor functional status at 1-year follow-up.
Another study by Ruiz-Garćıa and colleagues28 described a
novel neuronal cell surface antibody against the metabotropic
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glutamate receptor 2 (mGluR2) in 2 patients with paraneo-
plastic cerebellar ataxia. One of the patients was a 78-year-old
woman with progressive cerebellar ataxia with an initial re-
lapsing and remitting course who developed a small-cell cancer
of unknown origin. The other patient was a 3-year-old girl who
presented with steroid-responsive acute cerebellitis preceding the
diagnosis of an alveolar rhabdomyosarcoma. In both cases, the serum
and CSF antibodies immunolabeled the cell surface of cultured live
neurons and produced a neuropil-like immunostaining, particularly
involving the hippocampus and cerebellum. The antibodies did not
cross-react with other previously characterized mGluR antigens
(mGluR1 or mGluR5) and did not internalize the receptors. The
study suggests that mGluR2 antibodies are novel biomarkers of
paraneoplastic cerebellar ataxia and that the antibodies are potentially
pathogenic, although the mechanisms involved are different from
downregulation or receptor internalization. Although only 2 patients
were included in the study, the partial improvement of one of the
patients and full recovery of the other are noteworthy because par-
aneoplastic cerebellar ataxia rarely improves with treatment.
For themedical sleuths and those interested in the history of neurology,
Tényi and colleagues29 provided a likely resolution of a 190-
year-old unresolved medical case. These authors while
reviewing the historical medical literature found reference of a
patient reported in medical journals from Hungary, Italy, and
Germany. The patient was initially studied in 1830 and was
presented in 1841 at the third meeting of the Italian Scientists
held in Florence. Before symptom onset, she was a healthy 18-
year-old woman who developed seizures followed by a 6-day-
long clinical state characterized by unresponsiveness, catalepsy,
and shallow breathing. These symptoms apparently resolved
but returned over the following 18 months during which a
progressively growing abdominal tumor was identified. One
day she suddenly developed emesis that included pus and
blood mixed with more than 100 bone fragments. In addition,
she had evacuation from the anus and vagina of a membranous
substance mixed with blood and pus. After this event, the
seizures and catalepsy-like episodes resolved. Over the fol-
lowing years, she gave birth to 3 healthy children and was still
well 11 years later. Tényi and colleagues29 postulate that the
shallow breathing was likely due to hypoventilation, and the
catalepsy-like state was catatonia, which was not identified as
an entity until more than 40 years later. They also suggest that
the mass was likely an ovarian teratoma that can become very
large, contain bone, and perforate into the bowel and vagina.
This historical finding is remarkable; it probably represents the
first description of a paraneoplastic syndrome given that the
case predates by 35 years the description of Trousseau syn-
drome, which is considered the first paraneoplastic syndrome
reported.30
During the last year, the SARS-CoV-2 pandemic not only dominated
our lives and affected direct interactionswith our patients but also had a
prominent presence in neurology journals. In N2, 11 published ar-
ticles were centered on whether SARS-CoV-2 infects the CNS
or PNS, triggers neuro-autoimmunity, or increases suscepti-
bility to infection in patients on immunotherapies, shedding
light on the challenging concerns of neuroinvasion and
autoimmunity.
COVID-19–associated neurologic events, including strokes,
hypercoagulable state, hypoxic-ischemic, and toxic-metabolic
encephalopathies, were reported early this year,31 but evidence
that COVID-19 can trigger neuro-autoimmunity emerged
when GBS, the prototypic viral-triggered autoimmune disease,
was recognized almost concurrently in several worldwide
hotspots.11,12,32–34 A review in N2 by Dalakas10 synthesized
these cases pointing out that 2 early clinical and laboratory
signs, anosmia/ageusia, and lymphocytopenia/
thrombocytopenia are red flags in suspecting COVID-19
in asymptomatically infected individuals that present not
only with GBS but with any acute neurologic event. GBS
peaks 5–10 days after the first COVID-19 symptoms and can
present with multiple cranial neuropathies or Miller Fisher
syndrome (MFS).10,35 Other evolving COVID-19–triggered
autoimmunities were pointed out, including acute necrotiz-
ing autoimmune myositis, evidenced by high CK levels
(>10,000) in 10% of COVID-19–infected patients31 res-
ponding, whenever treated, to immunotherapy10,36; acute
necrotizing encephalopathy or brainstem encephalitis with
MRI-enhancing white matter lesions14,16; encephalitis with
increased CSF interleukin (IL)-1β, IL-6, and rapid recovery13;
and endothelial inflammation (endothelialitis) with encepha-
lopathy and meningeal enhancement responding to
immunotherapy.37
Because SARS-CoV-2 RNA shares 75%–80% genomic se-
quence with its 2 neurovirulent coronavirus predecessors,
Middle East respiratory syndrome coronavirus and SARS-
CoV, neuroinvasion was suspected considering its high viru-
lence and lethality. The sudden loss of smell and taste not only
in GBS but in up to 60% of COVID-19 carriers early in the
infection38 strengthened the view of viral entry into the
brain. In contrast to commonly reversible anosmia when
the non-neural olfactory epithelial cells are virally infected,
persistent anosmia/ageusia was suggestive of neuro-
tropism targeting olfactory neurons.38 In mice, oronasal
infection with SARS-CoV infects olfactory receptor neu-
rons in the neuroepithelium gaining access to the olfactory
bulb and brainstem.39 SARS-CoV may also enter the CNS
via retrograde axonal transport through the trigeminal
nerve nociceptive receptors in the nasal cavity and the
sensory fibers of glossopharyngeal nerves.39 The MRI-
enhanced oculomotor, trigeminal, and facial nerves observed
in patients with brainstem encephalitis or MFS strengthened
the notion of neuroinvasion or edematous neuro-
inflammation.35 SARS-CoV-2 invades cells by binding to
angiotensin-converting enzyme-2 (ACE2) receptors, re-
portedly expressed—although not fully substantiated—in
endothelial cells of brain vessels, nerves, and muscles, facili-
tating potential CNS and PNS entry.38 Macrophages also ex-
press ACE2 receptors that may carry the virus into neural
tissues, like HIV (Trojan horse phenomenon), augmenting
neuroinflammation and tissue injury.40 Notwithstanding its
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neuroinvasive potential however, most published data point to
COVID-19–triggered autoimmunity,10,35 as also summarized
by Bodro et al.13
A step toward clarifying the above was a pivotal study by
Alexopoulos et al.,19 who assessed in 8 patients with enceph-
alopathy whether anti–SARS-CoV-2 antibodies are in-
trathecally produced in response to locally persisting viral
antigens or are passively transferred into the CSF from the
circulation due to the impaired BBB. Anti–SARS-CoV-2 an-
tibodies were detected in the CSF of all patients, but 4/8 had
high titers comparable to their serum values denoting BBB
disruption; only 1/8 had anti–SARS-CoV-2 immunoglobulin
G (IgG) intrathecal synthesis.19 A disrupted BBB allows pas-
sive entry into the CNS not only of antibodies but also cir-
culating cytokines and inflammatory mediators, which may
affect endothelial cells, a structural part of the BBB, resulting in
endothelialitis and further BBB disruption. Anti–SARS-CoV-2
antibodies entering the CNS can, by mobilizing complement
or guiding SARS-CoV-2–infected macrophages, lead to acti-
vation of microglia or resident macrophages enhancing neu-
roinflammation and neurodegeneration, as supported by the
presence of 14-3-3 protein in 4/8 patients with poor out-
come.19 These observations highlight the need for prospective
CSF studies to determine the pathogenic role of anti–SARS-
CoV-2 antibodies or other neuroinflammatory molecules, ex-
plore markers of neurodegeneration, and guide early initiation
of proper therapeutic interventions.19 Considering that the
CSF from most published patients, not only with encepha-
lopathies but also with GBS and cranial neuropathies, has been
acellular and SARS-CoV-2–PCR negative,10,13,19 the possibil-
ity of intrathecal viral replication driven by locally persisting
viral antigens appears unlikely, except if there is rapid viral
clearance or unique compartmentalized immune response
within the CNS.
That SARS-CoV-2 triggers neuro-autoimmunity is addition-
ally supported by the data from COVID-19–triggered GBS
wheremany treated patients responded fast to IVIg, whereas at
least 2 examined patients harbored antibodies to GD1b
ganglioside,34,41 as seen in other postviral-induced GBS.10 As
pointed out,10 these antibodies are of significance because the
attachment of COVID-19 spike S protein to respiratory cells is
mediated not only by ACE2 receptors, but also by binding to
sialic acid–containing glycoproteins and gangliosides on cell
surfaces.42 Because in GBS and other autoimmune neuropa-
thies, gangliosides containing disialosyl moieties can serve as
antigens and anti-GD1b gangliosides are pathogenic,43 cross-
reactivity between epitopes within the COVID-19 spike–
bearing gangliosides and signature sugar moieties on nerve
glycolipidsmay representmolecularmimicry similar to the one
observed between nerve glycolipids and Campylobacter jejuni
or Zika virus–triggered GBS.10,35
Regarding common autoimmune neurologic disorders, like
MS, neuromyelitis optica spectrum disorder (NMOSD),
chronic inflammatory demyelinating polyneuropathy,
myasthenia gravis, or inflammatory myopathies, there is con-
vincing evidence that neither the disease itself nor the main-
tenance therapies they receive with steroids, mycophenolate,
or azathioprine increase susceptibility to COVID-19 or place
them into an immunosuppressed or immunocompromised
category; if clinically stable and not lymphopenic, there is no
need to alter therapies.10 The same applies to disease-
modifying therapies in patients with MS,1,3 especially be-
cause these therapies target mostly adaptive immunity with
insignificant effect on innate immunity that facilitates infection
of macrophages and viral spread,10 as also summarized by
Berger et al.1 For patients on monthly IVIg, there may be even
a theoretical advantage of IVIg offering natural protective au-
toantibodies. The anticomplement agent eculizumab, ap-
proved for NMOSD and myasthenia gravis, should not be
withheld as it may have an added protective benefit.10,44
Complement, being an integral component of the innate im-
mune response to viruses and an instigator of proinflammatory
responses, exacerbates SARS-CoV–associated respiratory
distress44,45; eculizumab, currently tested for the inflammatory
complications of COVID-19, already shows early benefits.46
Postponing or suspending cladribine, alemtuzumab, mitoxan-
trone, and hematopoietic stem cell transplantation is highly
advisable.47 For patients on rituximab (RTX) and ocrelizumab,
infusion intervals can be prolonged to more than 6 months, as
both B-cell reduction and clinical benefit persist longer.1,10,47
Notwithstanding the need to further explore the COVID-
19–driven acute events of neuro-autoimmunity or
neurovirulence, there is an urgent need to assess post-
neuroinflammatory effects in COVID-19 survivors. In anal-
ogy to postviral fatigue syndromes associated with less invasive
viruses, the post–COVID-19 neurologic sequelae are expected
to be profound considering the multisystemic effects of
COVID-19, even if many acute events are not directly caused
by the virus, as argued by Bodro et al.13 Many discharged
patients, as pointed out,10 are left with muscle weakness, at-
rophy, and gait imbalance; several have lost smell and taste;
and still others exhibit cognitive and mental issues, even after
short-term illness, compounded by social isolation, anxiety,
and fears. A systematic study of neurologic, cognitive, and
neuropsychological assessments is needed to help all recovered
patients return to normalcy.
T-helper 17 (Th17) cells are considered a hallmark
proinflammatory T-cell subset that participates in patho-
genesis of several organ-targeted autoimmune diseases,
including MS. IL-26, a member of the IL-10 cytokine
family, has been identified as a human Th17-associated
cytokine that is regulated by IL-1β, IL-23, and RAR-related
orphan receptor γt, the master regulator in Th17 differentia-
tion. IL-26 appears to have a proinflammatory role in in-
flammatory bowel disease48 and rheumatoid arthritis.49 In the
November issue ofN2, Broux et al.50 investigated the potential
role of IL-26 in MS. Based on the earlier observations in Th
differentiation and other autoimmune diseases, these authors
hypothesized that IL-26, like IL-17, would have a
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proinflammatory role and promote BBB disruption.51 Indeed,
they observed that IL-26 is preferentially expressed by Th17
cells. However, when examining the transcriptome of IL-26–
treated human BBB endothelial cells, they observed that IL-26
downregulated expression of proinflammatory cytokines, tu-
mor necrosis factor α, interferon (IFN)-γ, and IL-6. Further-
more, IL-26 promoted expression of certain BBB tight junction
(TJ) molecules, including JAM-1, and this effect was inhibited
by antibodies that prevented binding to the IL-26 receptor (R),
a heterodimer composed of IL-10R2 and IL-20R1. Although
mice do not express IL-26, they do express the IL-26R, which
permitted the authors to examine the influence of IL-26
treatment in mice. IL-26 treatment of mouse BBB endothelial
cells promoted expression of certain TJ proteins, including
JAM-1 and CLDN5. IL-26 treatment in vivo was associated
with reduced severity of clinical EAE, decreased CNS extrav-
asation of blood proteins, and reduced CNS infiltration of
Th17 cells. Conversely, IL-26 treatment was associated with an
increased CNS accumulation of Treg and Th10 cells, a well-
known regulatory T-cell subset. Thus, although IL-26 is
expressed by Th17 cells, this cytokine exhibits anti-
inflammatory characteristics, promoting BBB integrity and
CNS accumulation of regulatory T cells. The authors’ obser-
vations are exciting and raise additional questions. In further
studies, it will be important to determine whether all activities
of IL-26 are mediated through IL-10R2. It will also be im-
portant to determine how this cytokine influences antigen-
presenting cell (APC) function ofmyeloid cells and other APC
subpopulations. Given that IL-26 exerted proinflammatory
responses in 2 other organ-specific autoimmune diseases,48,49
one will need to be cautious in advancing IL-26 therapeutically
in MS. Clearly, more work is needed to further elucidate the
role of IL-26 in CNS autoimmune diseases.
Several disease-modifying therapies (DMTs) used for treatment
of MS cause alterations in cellular or humoral immunity that may
be sustained after treatment discontinuation. This is a particular
concern when a patient has breakthroughMS activity or develops
medication intolerance, leading one to consider subsequent al-
ternate therapy. Fingolimod (Gilenya), one of the S1P modula-
tors, traps lymphocytes in secondary lymphoid tissues, resulting in
reduced lymphocyte counts within peripheral blood.52 Fingoli-
mod is immunosuppressive, predisposing to viral infections,
including herpes simplex and varicella, and less commonlymay
be associated with progressivemultifocal leukoencephalopathy
in JC virus–seropositive patients.53 In a recent study published
in N2, Nagy et al. investigated the dynamics of immune cell
recovery in 58 patients after discontinuation of fingolimod
treatment.54 Surprisingly, 22% remained lymphopenic 1 year
later. Risk factors for sustained lymphopenia included low
baseline lymphocyte counts, prior treatment with mitoxan-
trone, and subsequent treatment with the anti-CD20, RTX.
Sustained lymphopenia in association with RTX may not be
surprising, as RTX can cause a near complete elimination of
peripheral blood B cells, which may account for approximately
15% of circulating lymphocytes. Regardless, the study by Nagy
underscores the concern for sustained immune suppression
when using certainDMTS sequentially and the need for careful
monitoring.
The MS DMT, alemtuzumab (Campath, Lemtrada), a
monoclonal antibody that targets CD52 and depletesmature B
and T cells, is highly effective in relapsing-remitting MS. In
contrast with fingolimod and other DMTs that pose greater
risk for viral infections or other consequences from immune
suppression, alemtuzumab is associated with risk for secondary
(iatrogenic) humoral autoimmunity in up to 40% of patients.
Signs or symptoms of 3 secondary autoimmune conditions,
Graves' disease, immune thrombocytopenia, or, more rarely,
antiglomerular basement membrane disease are delayed, oc-
curring more than 18 months after the first treatment course, a
time when there is B-cell hyperrepopulation and reduced
thymic T-cell reconstitution. Independent of alemtuzumab
treatment, the corresponding primary (idiopathic) humoral
autoimmune conditions are sometimes treated with anti-
CD20 B-cell depletion. Meltzer et al.55 therefore hypothesized
that scheduled anti-CD20 B-cell depletion could mitigate
against the risk for alemtuzumab-induced secondary autoim-
munity. In a 10-patient pilot study, they administered low-dose
(50–100 mg/m2) RTX after the first or second cycle of
alemtuzumab. Some of their patients were followed for a mean
of 41 months. They did not observe evidence of secondary
autoimmunity in any of their patients. Although their results
are provocative, additional studies are needed to confirm their
findings, establish how effectively low-dose RTX depletes
B cells, and determine whether concomitant treatment of anti-
CD52 and anti-CD20 provides greater benefit than approved
dosing with anti-CD20 alone. Of additional interest, cases of
paradoxical MS disease activation after alemtuzumab treat-
ment have also been reported.56,57 In these rare instances, RTX
has been administered and has been effective in stabilizing
those patients.
Whether MS and NMO influence susceptibility to COVID-19
infection are questions that have concerned patients and their
treating neurologists. Reports published in N2 early in the
COVID-19 pandemic have indicated that MS or NMO alone
does not confer greater susceptibility to either disease.3–5
However, a large study of patients with MS with confirmed
COVID-19 identified age, obesity, and Expanded Disability
Severity Score as independent risk factors for more severe
COVID-19 outcome.58 How individual DMTs alter risk of
COVID-19 is not clear. Because of the antiviral properties of
type I IFNs α and β, it has been suggested that IFN-β therapy in
MS could be protective against COVID-19.7 Whether anti-
CD20 B cell–depleting antibodies pose greater risk of COVID-
19 is not clear. A large study of patients with MS in Italy
identified a higher risk of severe outcome of COVID-19 in-
fection in patients withMS treatedwith ocrelizumab or RTX.59
In contrast, report of a pharmacovigilance case series con-
ducted by themanufacturer of ocrelizumab indicated that there
was no greater risk of severe COVID-19 outcome in
ocrelizumab-treated patients with MS. As B cells serve as the
source of antibody-secreting plasmablasts and plasma cells, one
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is also concerned whether anti–CD20-treated patients will
mount protective antibody responses to COVID-19 vaccines
that may soon become available. In this context, a recent study
observed that humoral responses to several nonlive vaccina-
tions were attenuated in patients with MS treated with ocre-
lizumab.60 It is clear that additional studies are needed before
considering recommendations regarding use of MS thera-
peutics and COVID-19 risk.
In recent years, myelin oligodendrocyte glycoprotein (MOG)-
associated disease (MOGAD) has emerged as immune-
mediated nosologic entity distinct from typical aquaporin-4
(AQP4) ab–positive NMOSD.61–63 Moreover, MOG sero-
positivity is rarely found in patients with classic MS.64 Avail-
ability of reliable assays to test for antibodies to MOG is
important for managing these patients. Here, an international
consortium examined several MOG antibody assays in a
multicenter approach.65 Thirty-nine clearly MOG-IgG–
positive sera, 39 low-positive sera, 13 borderline-negative sera,
40 clearly negative sera, and 30 sera from healthy blood donors
were distributed to 5 testing centers where several live and
fixed immunofluorescence cell-based assays, live flow cytom-
etry cell-based assays, and ELISA assays were performed.
Eighteen replicates (9 MOG-IgG positive and 9 negative)
served as technical controls. Agreement was excellent (96%)
between live cell-based assays for MOG-IgG in samples pre-
viously clearly identified as positive or negative, whereas
agreement was not as good for the fixed cell-based assay (90%).
Cell-based assays showed an excellent interassay re-
producibility, whereas ELISA failed to show concordance with
cell-based assays for detecting MOG-IgG. In contrast, the
agreement of cell-based assays for borderline negative and low
positive samples was much lower (77% and 33%, respectively).
This work has important implications for MOG-IgG testing
and interpretation of test results in clinical practice: (1) com-
mercially available fixed cell-based assays are useful when live
cell-based assays are not available; however, the former will
miss approximately 10%–15% of positive cases. This under-
scores the recommendation to retest patients with a typical
clinical presentation of MOGAD in a center offering live cell-
based assays when the fixed cell-based assay is negative; (2)
ELISAs are not adequate for the detection of MOG-IgG and
should therefore not be used; (3) the interpretation of bor-
derline seropositivity remains an unresolved issue until the
most useful cutoff for clinical purposes will have been estab-
lished. In the meantime, low-positive MOG-IgG is probably
only meaningful in conjunction with the suitable clinical pre-
sentation (in patients with ON, ADEM, myelitis, and some
forms of encephalitis) but not classic MS.
Another study from Korea reported a different biomarker
profile between AQP4 ab–positive NMOSD and MOGAD.66
AQP4 ab–positive patients with NMOSD had higher serum
levels of glial fibrillary acidic protein than patients with
MOGAD, and levels of this biomarker of astrocyte damage
were higher in relapse than remission in NMOSD but not in
MOGAD. Serum levels of another widely researchedmarker of
neuroaxonal damage, neurofilament light chain (NfL), were
comparable in both conditions, but only patients with
NMOSD had higher NfL values in relapse than in remission.
By contrast, only patients with MOGAD had higher serum tau
levels in relapse as compared to remission. These findings
emphasize distinct mechanisms of tissue damage in AQP4
ab–positive NMOSD and MOGAD and moreover propose
that tau, a microtubule-associated protein in neurons, could be
further investigated as clinically applicable biomarker in pa-
tients with MOGAD.
The question as to whether MOGAD should be treated with
immunotherapy right after the first clinical event is still con-
tentious owing to a presumably high proportion of mono-
phasic cases and an on average more favorable prognosis than
AQP4 ab–positive NMOSD. However, most experts would
advocate relapse-preventive immunotherapy after 2 or more
attacks.67 Unfortunately, data on the appropriate drugs for
treating MOGAD are still scarce. Although larger case series
have demonstrated good efficacy of oral corticosteroids and
generic immunosuppressants such as azathioprine and myco-
phenolate mofetil (MMF), the situation seems to be less clear
for RTX, and classic MS drugs were reported to be of no effect
or even harmful as in AQP4 ab–positive NMOSD.68,69 Against
this background, a prospective observational cohort study from
China, although not a randomized trial, provides valuable
clinical evidence on the effect of MMF on relapse rates in
MOGAD.70 Seventy-nine patients with MOGAD (children
and adults, 54 on MMF and 25 without MMF; both groups
had an additional and comparable steroid taper) were followed
over a median of 261 days (without MMF) and 472.5 days
(with MMF). Relapse rates were 7.4% in the w/ MMF group
and 44% in the w/o MMF group. MMF treatment was asso-
ciated with a profoundly reduced risk of relapse, even after
adjusting for covariates such as age group (children vs adults),
sex, disease course, and initial MOG-IgG titer (HR 0.08, 95%
CI 0.02–0.28, p < 0.001). Only 1 patient discontinued MMF
owing to side effects. Despite inherent limitations of this
noncontrolled trial, the results show that MMF might confer
effective attack prevention in patients with MOGAD.
Treatment with monoclonal antibodies (mAbs) is a thera-
peutic mainstay in many autoimmune diseases, which often
affect young females in child-bearing age.71–73 As disease ac-
tivity may be increased in the peripartum period in some
conditions, withholding immunotherapy may be hazardous for
the mother. On the other hand, women are often advised to
forego breastfeeding because of scant safety data on the use of
mAbs during this period, although both the mother and the
neonate may benefit from it. LaHue and colleagues conducted
a review of the medical literature and extracted data from 30
studies on breast milk concentrations of 19 mAbs (among
them natalizumab, RTX, tocilizumab, and eculizumab), which
were generally low.74 The relative infant dose, a parameter
comparing infant with maternal drug dose, was assessed for
some mAbs including RTX and natalizumab and was below
10%, which is generally considered safe. None of 368 infants
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followed for 6 or more months after exposure to breast milk of
mothers treated with mAbs had overt developmental delay or
serious infections. Despite some limitations, this work suggests
low mAb transfer into breast milk and may help inform in-
dividual treatment decisions as to mAb treatment during the
postpartum and lactation period. However, the authors rightly
call for registries to substantiate these findings. This review is
paralleled by another study in 9 women with MS who received
RTXwhile breastfeeding.75 In serial samples collected between
hours to several weeks from RTX infusion, maximum con-
centrations were attained 1–7 days after infusion and yielded a
relative infant dose of 0.08%. The authors conclude that RTX
therapy may confer an acceptable risk-to-benefit ratio, sup-
porting both maternal treatment and breastfeeding, in women
with severe neurologic autoimmune diseases.
Neuroinflammation, oxidative stress, and aging are linked to
cognitive risk in persons living with HIV (PLWH), even in
individuals achieving suppression of virus replication with
antiretroviral therapy.76 Several studies in the May 2020 issue
addressed the potential impact of these factors in PLWH.
Certain populations (distinguished by genetic background,
age, or other factors) may be more vulnerable to effects of
neuroinflammation and oxidative stress. In a study of 528
PLWH (276 African Americans and 252 European Ameri-
cans), Garza et al.77 showed that a common genetic regulatory
variation [(GT)n dinucleotide repeat length] in the promoter
region of the antioxidant enzyme, heme oxygenase-1 (HO-1),
is a unique risk factor for cognitive impairment in PLWH. The
presence of at least 1 short (GT)n repeat allele, which asso-
ciates with higher HO-1 expression, associated with a 2-fold
reduction in an individual’s cognitive impairment risk. Fur-
thermore, this reduced risk effect appears to be linked to
neuroinflammation, particularly in individuals of African an-
cestry. The implications are important. Because HO-1 is
therapeutically targetable (e.g., dimethyl fumarate), neurologic
complications of virus infections associated with neuro-
inflammation and oxidative stress (HIV, SARS-CoV-2, and others)
may potentially be preventable with HO-1–inducing drugs.78
Also, in the May 2020 issue, Groff et al.79 used magneto-
encephalography (MEG) and neuropsychological testing to
compare 77 PLWH with 93 HIV-negative controls to assess
the effects of HIV infection on the integrity of occipital-parietal
visual-spatial responses, which this group had shown before to
vary predictably with aging.80 Cognitively impaired PLWH
differed from unimpaired PLWH in age-dependent responses.
Although not specifically examined in this study, biomarkers of
neuroinflammation andoxidative stress increasewith age in the
HIV-infected brain, which suggests that studies linking MEG
responses with biomarkers of neuroinflammation linked to
cognitive impairment are warranted.
Neuroinflammation and the use of the recreational drug
cannabis (once considered a drug of abuse) in PLWH were
the subject of study by Ellis et al.81 in the September 2020
issue. In this study, plasma and CSF samples from 35 PLWH
and 21 HIV-negative controls matched for cannabis use (re-
cency, density, cumulative months, and grams) were analyzed.
The investigators found that recent cannabis use associated
with reduced neuroinflammation (indicated by reduced CSF
expression of IL-16, C-reactive protein, and soluble receptor
for TNF type II). This is not necessarily surprising, as CB2
receptors (CB2Rs) are expressed in microglia and astrocytes,
and CB2R activators have anti-inflammatory effects.82 This
study builds upon a body of literature that suggests some po-
tential neuroprotective effects of cannabis use and thus de-
fining specific effects of these is increasingly important as the
use of medical marijuana rises in PLWH.83
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